NOVOTECH HEALTH


Associated tags: Fine chemical, Cros, Drug development, AU, Gene, Pharmaceutical industry, Cell, IND, Research, NDA

Locations: EUROPE, US, CHINA, ASIA, NORTH AMERICA

The Evolving Global Landscape in Vaccine Development: Novotech and Endpoints News Webinar

Retrieved on: 
Wednesday, February 15, 2023

SYDNEY, AU, Feb 15, 2023 - (ACN Newswire) - Novotech, the leading Asia Pacific centred biotech CRO with extensive experience in vaccine trials, is convening an expert panel webinar covering the evolving landscape in vaccine development.

Key Points: 
  • SYDNEY, AU, Feb 15, 2023 - (ACN Newswire) - Novotech, the leading Asia Pacific centred biotech CRO with extensive experience in vaccine trials, is convening an expert panel webinar covering the evolving landscape in vaccine development.
  • https://novotech-cro.com/whitepapers/vaccines-asia-pacific-clinical-tria...
    The webinar, Keeping pace with the evolving global landscape in vaccine development, will hear from a panel of life science experts on the latest advancements and innovative modalities paving the way in the global vaccine development space including:
    - The COVID-19 impact on drug development and the regulatory landscape.
  • - Key factors contributing to Asia Pacific being recognised as the hub for vaccine development and opportunities for biotech's to leverage.
  • - Key considerations for pre-clinical and clinical planning to accelerate vaccine development, supporting a robust global strategy.

Novotech Global Report: Robust Phase 1 Trial Growth Across Asia Pacific

Retrieved on: 
Friday, February 10, 2023

SYDNEY, AU, Feb 10, 2023 - (ACN Newswire) - Novotech, the leading Asia Pacific centred biotech CRO, has published a new global report on Phase 1 trial activity including current metrics on fast growth regions and therapeutic areas.

Key Points: 
  • SYDNEY, AU, Feb 10, 2023 - (ACN Newswire) - Novotech, the leading Asia Pacific centred biotech CRO, has published a new global report on Phase 1 trial activity including current metrics on fast growth regions and therapeutic areas.
  • According to the report, titled "Phase I Global Clinical Trial Landscape - Focus on Asia Pacific", in 2022 Asia Pacific accounted for a 58% share of the approximately 3,600 Phase I trials initiated globally in 2022.
  • The report found that Asia Pacific also leads phase I trials across the top therapeutic areas.
  • View "Phase I Global Clinical Trial Landscape - Focus on Asia Pacific", the new report, on this link: https://tinyurl.com/novotech-global-report
    See the report for Phase 1 location and therapeutic area analysis including:

Asia Pacific Cell & Gene Research Growing 50% Faster than ROW

Retrieved on: 
Friday, February 3, 2023

SYDNEY, AU, Feb 3, 2023 - (ACN Newswire) - Novotech, the leading Asia Pacific focused biotech specialist CRO and recipient of the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence award, said the number of cell & gene therapy trials in the region was growing 50% faster than ROW.

Key Points: 
  • SYDNEY, AU, Feb 3, 2023 - (ACN Newswire) - Novotech, the leading Asia Pacific focused biotech specialist CRO and recipient of the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence award, said the number of cell & gene therapy trials in the region was growing 50% faster than ROW.
  • Novotech, which has extensive experience in cell & gene therapy clinical trials, is sponsoring the 6th Annual Cell And Gene Therapy Innovation Summit in Berlin, Germany (15-16 February 2023).
  • The latest data shows Asia Pacific is the fastest-growing region globally for cell & gene therapy trials representing more than a third of all cell & gene studies, with China leading in the region.
  • The region already accounts for over a third of cell & gene therapy trial activity and shows a nearly 50% faster growth rate in cell & gene therapy trials compared to ROW between 2016 and 2021.

Novotech Acquires US-based Drug Development Consulting Firm, CBR International

Retrieved on: 
Thursday, January 12, 2023

CBR adds a group of experts to Novotech to provide US and global regulatory, scientific, quality, and clinical development services.

Key Points: 
  • CBR adds a group of experts to Novotech to provide US and global regulatory, scientific, quality, and clinical development services.
  • Novotech CEO Dr. John Moller said: "CBR will provide decades of FDA regulatory experience for our biotech clients.
  • Navigating novel product development and achieving multiple approvals has built our expertise to support the complex development needs of clients worldwide which will now support Novotech clients.
  • We look forward to working with Novotech clients to support their drug development programs in the US and globally.

Novotech is Gold Sponsor at Biotech Showcase 2023

Retrieved on: 
Tuesday, December 20, 2022

SYDNEY, AU, Dec 20, 2022 - (ACN Newswire) - Novotech, the Asia Pacific centered biotech specialist CRO is proud to be Gold Sponsor at Biotech Showcase 2023.

Key Points: 
  • SYDNEY, AU, Dec 20, 2022 - (ACN Newswire) - Novotech, the Asia Pacific centered biotech specialist CRO is proud to be Gold Sponsor at Biotech Showcase 2023.
  • Novotech CEO Dr. John Moller and experts from the Novotech US and Asia Pacific teams will be attending the conference.
  • Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions in Asia Pacific delivering exclusive benefits for sponsors.
  • The latest industry research publication by GlobalData and Novotech found almost 50% of new trials globally have sites in Asia Pacific.

Data Shows 50% of New Trials Have Sites in Asia Pacific

Retrieved on: 
Sunday, December 18, 2022

SYDNEY, AU, Dec 15, 2022 - (ACN Newswire) - Novotech, the Asia Pacific centered biotech specialist CRO said the latest industry research publication by GlobalData and Novotech found almost 50% of new trials had sites in Asia Pacific.

Key Points: 
  • SYDNEY, AU, Dec 15, 2022 - (ACN Newswire) - Novotech, the Asia Pacific centered biotech specialist CRO said the latest industry research publication by GlobalData and Novotech found almost 50% of new trials had sites in Asia Pacific.
  • According to the new publication titled "State of the Global Biotech Landscape: Where the Opportunities Lie", demand for Asia Pacific trial sites is strong with almost half of the more than 27,000 clinical trials initiated in 2021 having sites in Asia Pacific.
  • The data shows almost 12,900 of the new trials had sites in Asia Pacific.
  • - Phases I and II were dominated by Asia Pacific, which served as a trial location in 57% and 49% of trials, respectively.

Novotech Awarded the Asia Pacific CRO of the Year 2022 for Best Practices in Clinical Trials

Retrieved on: 
Tuesday, December 6, 2022

SYDNEY, AU, Dec 6, 2022 - (ACN Newswire) - Novotech, the leading Asia Pacific biotech specialist CRO, has been awarded the Frost & Sullivan Company of the Year Award 2022 for Best Practices in the Asia-Pacific contract research organization industry.

Key Points: 
  • SYDNEY, AU, Dec 6, 2022 - (ACN Newswire) - Novotech, the leading Asia Pacific biotech specialist CRO, has been awarded the Frost & Sullivan Company of the Year Award 2022 for Best Practices in the Asia-Pacific contract research organization industry.
  • Novotech has been a recipient of the Frost & Sullivan Asia Pacific Best Practices awards since 2006.
  • Frost & Sullivan said: "Our approach involves the deployment of best practices and strategic analytics across a value chain.
  • Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US.